pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Mayzent
drug
save

siponimod fumarate

Marketedupdated 2mo ago
by $NVS NOVARTIS AG
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying siponimod fumarate

  • —Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patientscompletedn=451

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 27, 2028
~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

  • Apr 23, 2036method-of-use (U-3889)US 11944602
  • Apr 23, 2036method-of-use (U-3889)US 11944602
  • Apr 23, 2036method-of-use (U-3889)US 11944602
  • Apr 23, 2036method-of-use (U-4407)US 12533340
  • Apr 23, 2036method-of-use (U-4407)US 12533340
  • Apr 23, 2036method-of-use (U-4407)US 12533340
  • Jan 5, 2032formulationUS 12071402
  • Jan 5, 2032formulationUS 12071402
  • Jan 5, 2032formulationUS 12071402
  • Nov 30, 2030method-of-use (U-2511)US 84924414.4y
  • Nov 30, 2030method-of-use (U-2511)US 84924414.4y
  • Nov 30, 2030method-of-use (U-2511)US 84924414.4y
  • Aug 27, 2028compositionUS 79395192.1y
  • Aug 27, 2028compositionUS 79395192.1y
  • Aug 27, 2028compositionUS 79395192.1y

News(0)

no news has mentioned this drug yet

brand
Mayzent
generic
siponimod fumarate
indication
Relapsing Remitting Multiple Sclerosis (RRMS)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 3m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?